Company: RNAC
Filing Date: 2025-01-08
Form Type: 424B7
Source: 0001140361-25-000631
Chunk: 13

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-01-08
Form: 424B7
Chunk 13
---
 length of such deferral period; |

| • | the procedures for auction and remarketing, if any; |

| • | the provisions for a sinking fund, if any; |

| • | the provision for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights; |

| • | any listing of the preferred stock on any securities exchange or market; |

| • | the terms and conditions, if applicable, upon which the preferred stock will be convertible into Common Stock, including the conversion price (or manner of calculation) and conversion period; |

| • | whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price, or how it will be calculated, and the exchange period; |

| • | voting rights, if any, of the preferred stock; |

| • | preemptive rights, if any; |

| • | restrictions on transfer, sale or other assignment, if any; |

| • | whether interests in the preferred stock will be represented by depositary shares; |

| • | a discussion of any material and/or special U.S. federal income tax considerations applicable to the preferred stock; |

| • | the relative ranking and preferences of the preferred stock as to dividend rights and rights upon the liquidation, dissolution or winding up of our affairs; |

| • | any limitations on issuance of any class or series of preferred stock ranking senior to or on a parity with the class or series of preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of our affairs; and |

| • | any other specific terms, preferences, rights, limitations or restrictions of the preferred stock. |

Our Board of Directors could authorize the issuance of shares of preferred stock with terms and conditions that could have the effect of discouraging a takeover or other transaction that might involve a premium price for holders of the shares or which holders might believe to be in their best interests. The issuance of preferred stock could adversely affect the voting power, conversion or other rights of holders of Common Stock and reduce the likelihood that common stockholders will receive dividend payments and payments upon liquidation. The laws of the State of Delaware provide that the holders of preferred stock will have the right to vote separately as a class on any proposal involving fundamental changes to the rights of holders of such preferred stock. This right is in addition to any voting rights that may be provided for in the applicable certificate of designations. The transfer agent and registrar for any series of preferred stock